Inari Medical Stock News

Inari Medical (NARI) said the first patient was enrolled in a trial, dubbed PEERLESS, comparing the outcomes of patients with intermediate-high risk pulmonary embolism ((PE)) treated…

IRVINE, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patien

IRVINE, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today that it will release its fourth quarter and full-year financial results on Wednesday, February 23, 2022. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

IRVINE, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients

IRVINE, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patien

IRVINE, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients

Inari Medical (NARI) posts solid fourth-quarter and full-year 2021 revenue data, courtesy of resilience shown in the face of the COVID-19 induced challenges.

Inari Medical (NARI) posts solid fourth-quarter and full-year 2021 revenue data, courtesy of resilience shown in the face of the COVID-19 induced challenges.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BioAtla, Bristol-Myers Squibb Announce Collaboration To Evaluate ADC-Opdivo Combo In Solid Tumors BioA

Futures Rebound As Fed-Induced Rout Finally Eases After yesterday''s miraculous tech recovery which saw gigacaps drop as much as 4% before recovering all losses and closing green, Nasdaq futures led gains among U.S. stock-index futures, hinting at further relief for technology stocks as Treasury yields retreated in early trading but have since steadied around 1.75%, unchanged from Monday. Nasdaq futures rose as much as 0.7%, while S&P 500 and Dow Jones contracts were also higher by about 0.4% ahead of Powells Senate confirmation hearing for second term as Fed chair which begins at 10am and where the Fed chair is expected to put on a dovish mask and walk back some of the recent hawkish commentary. Dip-buyers rescued the Nasdaq from a fifth session of declines on Monday after Marko Kolanovic urged JPM clients to buy the dip, writing that yields aren''t too high and the Fed''s won''t derail the economys rebound. We view the recent equity volatility as an adjustment to the Feds incrementally more hawkish stance, rather than a sign that the Fed is about to bring the recovery and the equity rally abruptly to an end, Mark Haefele, chief investment officer at UBS Global Wealth Management, said in a note. We now expect three Fed rate hikes this year, starting as soon as March. We are looking for opportunities to raise our weighting in stocks in 2022, according to Luca Paolini, chief strategist at Pictet Asset Management, whose firm has a neutral stance on equities. The global recovery remains resilient, thanks to a strong labor market, pent-up demand for services and healthy corporate balance sheets. In his second term confirmation hearing before the Senate Banking Committee at 10am ET today, Fed Chair Jerome Powell will say the central bank will keep inflation from becoming entrenched, but the post-pandemic economy may look different from previous expansions.

Inari Medical Inc (NASDAQ: NARI) expects Q4 FY21 sales of $82.8 million - $83.3 million, up 14% sequentially and 71% year-over-year (at the midpoint of the range), beating the consensus of $73.16 m

Gainers: Accolade ACCD +13%, Inari Medical NARI +10%, Cellectis (CLLS) +6%, Intel INTC +5%, Ulta Beauty (ULTA) +4%. Losers: Patrick Industries (PATK) -40%, Rivian Automotive

IRVINE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patien

IRVINE, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patien

IRVINE, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients